This study was funded by Bristol Myers Squibb. J Mascarenhas reports consultancy fees from AbbVie, Bristol Myers Squibb, CTI BioPharma, Galecto, GSK, Incyte, Kartos Therapeutics, Karyopharm Therapeutics, MorphoSys, Novartis, PharmaEssentia, Roche and Sierra Oncology; payment or honoraria from AbbVie, Bristol Myers Squibb and MorphoSys; participation on a data safety monitoring board or advisory board for Galecto; and research funding from AbbVie, Bristol Myers Squibb, CTI BioPharma, Incyte, Kartos Therapeutics, Novartis and PharmaEssentia. H Nguyen and A Saunders report employment with and stock ownership in Bristol Myers Squibb. L Oliver and H Tomkinson were employees of Adelphi Values PROVE when this research was conducted. R Perry reports employment with Adelphi Values PROVE. A McBride reports employment with Bristol Myers Squibb. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Medical writing and editorial support were provided by Niamh Burke, PhD, of Excerpta Medica, funded by Bristol Myers Squibb.